We recognized early on that while weight loss is the goal, muscle loss is a common and unwanted side effect of potent GLP-1 medications
The compounds classification as a triple receptor agonist targeting GLP-1, GIP and glucagon receptors puts it at the forefront of metabolic research, giving scientists a way to study energy balance and glucose metabolism
The clinic does not set expectations for ongoing video or phone visits with a provider after the initial intake assessment, and the portal itself offers no monthly check-in cadence in writing
The participant, investigator and sponsor were blinded to bimagrumab dose or placebobimagrumab until database lock to avoid bias in reporting adverse events and efficacy
Mark Cuban has drawn national attention to Pharmacy Benefit Managers, arguing they abuse market power and raise prescription drug costs
People tracking their before and after semaglutide results often see these lipid improvements alongside body composition changes